Who Is at Risk of Postpartum Psychosis—and Is It Treatable?

A photo of a new mother holding her baby.

Having a baby can turn your world upside down.

Many new mothers experience a feeling of sadness that may last for a few weeks and go away on its own. And about one in eight women reported signs of a more significant postpartum depression, according to the Centers for Disease Control and Prevention (CDC).

A much smaller group of women, about one in a thousand, have a far more severe concern called postpartum psychosis. For years, there has been little awareness of postpartum psychosis. Lately, the condition has been in the news. When caught early, postpartum psychosis can be treated successfully.

In this Q&A, Veerle Bergink, MD, PhD, a psychiatrist and Director of Mount Sinai’s Women’s Mental Health Center, explains some of the key symptoms of postpartum psychosis, its likely causes, and some possible treatments.

A photo of Veerle Bergink, MD, PhD

Veerle Bergink, MD, PhD

“The most important thing to know is that postpartum psychosis is very treatable,” Dr. Bergink says. “If you detect and treat it, the woman will be fine. In our study, 98 percent of women got better, sometimes within days or weeks.” Under her leadership, Mount Sinai is researching the diagnosis and treatment of postpartum psychosis and has played a major role in attempting to shed light on this often-ignored condition.

How do you diagnose postpartum psychosis?

Postpartum psychosis is a severe mental illness that shows up during the first three months after childbirth. Women with this condition can display mania, psychosis, or depression with psychotic features. They may have these symptoms: 

  • Mania: When someone has a manic episode, thoughts race through their heads. They may behave in ways that are excessive. Sometimes people buy a lot, or they have grand plans. Their moods can be really over the top. They’re not happy, they’re over the moon. Or they are very irritable, they’re very, very annoyed by everyone and everything. 
  • Psychosis: This is when someone loses touch with reality. They may hear things that no one else does or see things that are not there. They might have weird ideas or become extremely paranoid or have delusions of grandiosity, religion or guilt. 
  • Depression with psychotic features: This is when someone’s mood is really low, and at the same time, they have lost touch with reality. For example, they don’t think that their child is crying a lot today but that they are the devil. They don’t think they’re responsible for a minor disagreement but that all wars are their fault.

These symptoms can vary, too. A woman might have mania, then dive quickly into a depression. She might have mania and depression at the same time. Or she might have symptoms one day, seem normal the next day, then display symptoms again later.

How does this look to family and friends?

Basically, you have a sense that something is off. You might think, “I know my sister, daughter, wife, and this is not her.”

How serious is postpartum psychosis?

Postpartum psychosis is very serious. If left untreated, there is a high risk of suicide. The  infanticide risk is very low, but if it happens it gets understandably a lot of media attention. Fortunately, it is highly treatable.

What are treatments for postpartum psychosis?

To treat postpartum psychosis, we start women with antipsychotic medication and lithium. Antipsychotics can be tapered after the acute phase (usually a few weeks) and women are advised to take lithium for one  year and then taper. Electroconvulsive therapy works as good as lithium. If a woman who had postpartum psychosis gets pregnant again, we advise to restart treatment the same day after they give birth to prevent another episode. There is no risk of postpartum psychosis during pregnancy, just after delivery. Women with bipolar disorder are at high risk for postpartum psychosis as well. They can prevent it by taking medication immediately after delivery.

It is also vital to make sure women with postpartum psychosis get enough sleep. They need a partner who can provide all the infant care overnight so the woman can sleep. This is especially key during the first few days and weeks after the birth. 

What causes postpartum psychosis?

We are not sure exactly what causes postpartum psychosis, but we do have several ideas. After women give birth, they experience a sudden, sharp decrease in estrogen and progesterone called a “hormone free fall.” We think this is one of the triggers. But when researchers tried to prevent this freefall with hormone replacement therapy, it didn’t protect women from experiencing postpartum psychosis. So, while hormone free fall probably contributes to postpartum psychosis, it isn’t the sole cause.

What else might be involved?

We think the immune system is also part of the problem. While a woman is pregnant, her immune system adapts to avoid rejecting the fetus the way it might reject a donated liver or kidney. But after she gives birth, the immune system goes back to the way it had been. Most autoimmune diseases have a flare-up after delivery. We know, for instance, that women with rheumatoid arthritis usually feel better during pregnancy. But after they give birth, the rheumatoid arthritis symptoms come back. Given that all disorders with postpartum onset in general medicine are immune related, we think that immune dysfunction plays a major role in postpartum psychosis as well. We have done small studies and urgently need funding for larger studies.

Who is most likely to develop postpartum psychosis?

It is just bad luck. Postpartum psychosis happens in women of all backgrounds and educational levels all over the world. But there are two groups of women who have a very high risk of postpartum psychosis:

  • Women who have bipolar disorder: Their risk goes from 1 in 1,000 to 1 in 6 for postpartum psychosis and 1 in 6 for postpartum depression. So that means women with bipolar disorder have a 1 in 3 risk for becoming mentally ill after childbirth.
  • Women who have already had postpartum psychosis: Their risk also rises from 1 in 1,000 to 1 in 3 to get seriously ill after delivery (both postpartum depression and postpartum psychosis)

How do I reduce my risk of postpartum psychosis?

If you are at high risk of postpartum psychosis, you should begin treatment right after you give birth to prevent it.

What does scientific research say about postpartum psychosis?

Recent studies have underlined the link between the condition and bipolar disorder. Researchers are working hard to spread the word about postpartum psychosis and have it recognized as an official diagnosis.

 

Four Faculty Members in the Department of Psychiatry Receive Distinguished Faculty Awards

Four faculty members in the Department of Psychiatry were recognized with Distinguished Faculty Awards from the Division of Psychology. The four recipients of these awards showcase excellence in clinical care, faculty mentorship, innovation, and leadership.

Shilpa Taufique, PhD, Chief of the Division of Psychology and Vice Chair for Faculty Development in Psychiatry, presented these awards at the 2026 Psychology Graduation.

“Our faculty are the foundation of our Division’s excellence, advancing patient care, education, research, and innovation every day. These Distinguished Faculty Award recipients exemplify the talent, dedication, and leadership that inspire our community and shape the future of academic psychology,” she said.

Distinguished Faculty Award Clinical Excellence 2026

A photo of Gregory Gagnon, PhD

Gregory Gagnon, PhD

Gregory Gagnon, PhD, Assistant Professor of Psychiatry, exemplifies sustained clinical excellence through his leadership, expertise, and unwavering commitment to patient care across both inpatient and outpatient settings.

As the supervising psychologist on the general adult inpatient unit and in the integrated outpatient service at the Mount Sinai-Behavioral Health Center, Dr. Gagnon consistently provides exceptional care to patients with complex clinical presentations while maintaining a strong focus on ethics, access, and quality. He has expanded clinical services through the introduction of Mentalization-Based Treatment (MBT) and other group treatment modalities, enhancing care options for patients.

In addition to his clinical contributions, Dr. Gagnon plays a vital role in developing the next generation of psychologists through his work as Assistant Training Director, overseeing a large externship program and providing outstanding clinical teaching and mentorship. His ability to seamlessly integrate clinical excellence, program development, and educational leadership makes him deeply deserving of this recognition.

Distinguished Faculty Award Education and Mentorship 2026

A photo of Elizabeth Ochoa, PhD

Elizabeth Ochoa, PhD

The career of Elizabeth Ochoa, PhD, Assistant Professor of Psychiatry, has been defined by an extraordinary commitment to education, mentorship, and the development of future generations of psychologists.

Over more than three decades at Mount Sinai Beth Israel, and now at the Mount Sinai-Behavioral Health Center, she has provided visionary leadership of the Psychology Internship Training Program, guiding it through multiple successful accreditation cycles and fostering a training environment known for its excellence in clinical education, supervision, and professional development.

As Chief Psychologist since 2009, she has mentored countless trainees, junior faculty, and colleagues across all stages of their careers, earning a reputation for her generosity, wisdom, and unwavering investment in the growth of others. Her leadership was instrumental in ensuring the continuity and success of the training program during its transition to the Behavioral Health Center, preserving a strong culture of learning and mentorship. Through her teaching, scholarly contributions, advocacy for the profession, and profound impact on the careers of generations of psychologists, Dr. Ochoa has left an enduring legacy that exemplifies the very best of education and mentorship in academic psychology.

Distinguished Faculty Award Scholarship and Innovation 2026

A photo of Yulia Landa, PsyD

Yulia Landa, PsyD

Yulia Landa, PsyD, Associate Professor of Psychiatry, is a nationally recognized clinician-scientist whose scholarship and innovation have transformed the field of psychosis prevention and early intervention.

Through a highly productive, federally funded research program, she has developed rigorously evaluated novel and scalable interventions that improve identification, engagement, and treatment for individuals at risk for or experiencing psychosis. Her pioneering work—including Cognitive Behavioral Therapy for clinical high-risk populations, Early Stage Identification and Engagement, and the ComPsych communication framework—has advanced both the science and practice of care, with widespread dissemination across clinical, community, and training settings.

Beyond intervention development, Dr. Landa has distinguished herself through her commitment to implementation, clinician training, and systems-level change, ensuring that evidence-based innovations reach the patients and families who need them most. Her national leadership, influential collaborations, extensive scholarly contributions, and extraordinary mentorship of emerging clinician-scientists have left a lasting impact on the field and exemplify the very highest standards of scholarship, innovation, and translational research.

Distinguished Faculty Award Leadership and Systems Impact 2026

A photo of Ashley Doukas, PhD

Ashley Doukas, PhD

Ashley Doukas, PhD, Assistant Professor of Psychology, has demonstrated exceptional leadership and system-level impact through her vision, operational excellence, and commitment to expanding access to high-quality behavioral health care.

As Clinical Director of the Center for Stress, Resilience and Personal Growth, she has transformed and significantly expanded a unique service dedicated to supporting Mount Sinai health care workers, their adult dependents, and other trauma-exposed populations. Under her leadership, the program has grown into a thriving multidisciplinary service, maintaining timely access to care while achieving outstanding clinical outcomes. She provides exemplary oversight of clinical operations, workforce development, supervision, and care pathways, ensuring that evidence-based practices are delivered with consistency and excellence.

Dr. Doukas has also demonstrated a strong commitment to sustainability and innovation, guiding the continued growth and financial viability of the program while contributing to scholarship that has advanced understanding of effective mental health interventions for health care workers. Through her leadership, teaching, mentorship, and dedication to supporting the well-being of the health care workforce, she has created lasting institutional impact and exemplifies the highest standards of leadership in academic health care.

Thinking of Stopping Your Antidepressant? Talk With Your Doctor First

A stock image of a man looking at a prescription medicine container

Antidepressants are a common treatment for depression. More than one in ten people in the United States take prescription medicine for depression, according to the Centers for Disease Control and Prevention.

These medicines are now in the spotlight amid an ongoing debate over how well they work and their possible side effects.

In this Q&A, Amirhossein Modabbernia, MD, PhD, Assistant Professor of Psychiatry, Icahn School of Medicine at Mount Sinai, explains how antidepressants can help. He also explains what you can do if they do not seem to be working, including how to talk with your doctor about stopping your medication.

“I think people should know that depression is real, common, and treatable, and that needing medication is not a weakness or a moral failure,” he says. “At the same time, antidepressants are not magic, and they are not the right answer for every person or every situation.”

How can antidepressants help people with depression?

Antidepressants can help many people. They may be most helpful when depression is moderate or severe, lasts a long time, or keeps coming back. These medicines can lower symptoms enough so a person can sleep, think clearly, connect with others, work, enjoy life, and start dealing with life’s problems again.

In my work with patients, people often describe the change by saying, “Something has lifted,” “I can think and function again,” or “There is a little more space between me and the depression.” Large studies do show that antidepressants outperform placebo on average, though the benefit varies substantially from person to person. Medication is not the whole answer for everyone. But for many people, it can create the mental and emotional space needed for recovery, therapy, relationships, and meaningful life changes.

A portrait of Amirhossein Modabbernia, MD, PhD

Amirhossein Modabbernia, MD, PhD

What if I am taking an antidepressant but do not feel better?

The first thing I would say is: Please talk honestly with your doctor. A poor response does not mean treatment has failed forever. It also does not mean you should stop the medicine suddenly. It is  important to have realistic expectations. Antidepressants usually do not create instant happiness. They do not take away all emotional pain. Early signs of improvement can be small. You may sleep better, have more energy, feel less weighed down, think more clearly, feel less irritable, or find it easier to get through the day.

What can I do if my antidepressant does not seem to be working?

If the medicine is not helping enough, that is useful information. It may mean:

  • The dose is not right.
  • The medicine needs more time to work.
  • Side effects are getting in the way.
  • The diagnosis needs to be looked at again.
  • Other issues are playing a role, such as sleep problems, substance use, medical problems, trauma, or major life stress.

Sometimes psyhotherapy needs to be added. Sometimes the medicine needs to be changed. Sometimes the whole treatment plan needs to be adjusted. The important point is this: If you are not improving, that is not a dead end. It is a reason to talk with your clinician and decide what to do next. If you feel worse, have side effects you cannot tolerate, or have suicidal thoughts, talk with a clinician right away.

What should I do if I want to stop taking my antidepressant?

Do not stop suddenly unless there is a clear medical reason and a clinician is guiding you. Stopping an antidepressant can be a reasonable choice. But it should be done with care. Before stopping, you and your clinician may want to talk about questions such as:

  • Why do I want to stop now?
  • How long have I been feeling well?
  • How stable is my life right now?
  • What happened the last time I stopped, if I stopped before?
  • What symptoms should we watch for?
  • How slowly should I lower the dose?
  • What is the plan if depression comes back?

Withdrawal symptoms are real. They can include dizziness, nausea, trouble sleeping, irritability, anxiety, vivid dreams, flu-like symptoms, and sometimes “brain zaps,” which can feel like electric shocks. This does not mean people should be afraid to stop. It means stopping should be planned. It should be done slowly, with a clear follow-up plan.

How do you decide if someone is ready to lower the dose?

I usually want to know if the person has been well—not just a little better—for a steady period of time. I also look at whether the person is functioning well again. I want to know if major stressors are stable, if the person has support, and if there is a plan to prevent depression from returning. That plan might include therapy, steady sleep routines, exercise, social connection, awareness of early warning signs, and a clear plan for what to do if symptoms return.

I also look closely at the person’s history. Someone who had one mild episode of depression is different from someone with depression that keeps coming back, or someone with long-term depression, suicidal thoughts, a history of hospitalization, severe anxiety, trauma, substance use, or possible bipolar disorder. Past attempts to stop medicine also matter.

Many guidelines recommend staying on antidepressants for several months after symptoms improve after a first episode. They recommend staying on them longer when depression has come back, lasted a long time, or been severe. So tapering is not only about preference. It is also about timing and safety. Is this a good time to try? And do we have a plan if symptoms get worse?

Are some antidepressants harder to stop than others?

Yes. Some antidepressants are more likely to cause symptoms when they are stopped, especially if they are stopped too quickly. In general, medicines that leave the body quickly can be harder for some people to stop. Examples include paroxetine, brand name Paxil, and venlafaxine, brand name Effexor. Fluoxetine, brand name Prozac, often causes fewer symptoms when stopping because it stays in the body longer. But every person is different. That is why the taper needs to be personalized.

Are there options other than antidepressants?

Yes. Antidepressants are only one part of depression treatment. Therapy can be very helpful. This can include cognitive behavioral therapy, also known as CBT; interpersonal therapy; behavioral activation; psychodynamic therapy; and mindfulness-based approaches. For many people, therapy is as important as medicine, and sometimes it’s more important.

It is also important to look at the full picture. Sleep, substance use, exercise, social isolation, daily routine, trauma, medical issues, and the person’s life circumstances all matter. Depression does not happen in a vacuum. For more severe depression, or depression that has not improved with treatment, other options may be appropriate. These can include transcranial magnetic stimulation, electroconvulsive therapy, or ketamine or esketamine. The right approach depends on the person. It depends on the severity of depression, safety, past treatment response, preferences, access, and what is realistic in that person’s life.

Why should I talk with a clinician?

Good treatment should be a partnership. People should feel able to ask questions and speak honestly about what they are experiencing. Tell your clinician if your medicine is not helping, if side effects are affecting your life, if you feel emotionally numb, or if you want to stop taking the medicine. These are all valid things to discuss. The goal is not just to lower symptoms on a checklist. The goal is to help people return to a life that feels more livable, connected, and meaningful.

How Can I Manage Social Anxiety? Three Tips From a Mount Sinai Psychologist

Avoiding other people from time to time is normal. But if you isolate yourself out of fear of embarrassment or rejection, you may have social anxiety disorder.

Charissa Chamorro, PhD

In this Q&A, Charissa Chamorro, PhD, a Mount Sinai clinical psychologist, explains how to know if you might have social anxiety disorder and what you can do to be more confident around others.

“Treatment isn’t about getting rid of anxiety—it’s about learning you can feel anxious and still engage meaningfully. The more you approach instead of avoiding, the more confidence you build,” says Dr. Chamorro, Assistant Clinical Professor, Psychiatry, Icahn School of Medicine at Mount Sinai.

What is the difference between being shy and having social anxiety disorder?

Social anxiety disorder is a diagnosable mental health condition. Shyness is considered a personality trait that can be shaped by temperament and experiences. While shyness usually involves mild discomfort in social settings, social anxiety involves a persistent, intense fear of being judged, embarrassed, or rejected.

Unlike shyness, social anxiety interferes with your life. If you avoid situations you actually want to be part of or cancel plans because of discomfort, you may have social anxiety disorder.

What causes social anxiety disorder?

The causes are thought to be a combination of biological and environmental factors, but not necessarily due to bullying or poor parenting. Some people are more prone to anxiety, and experiences like negative social feedback can reinforce that.

What are signs I might have social anxiety disorder?

  • Avoiding social interactions: Not just avoiding parties, but isolating yourself at work or having a hard time starting conversations with co-workers.
  • Going blank in conversations: You may blame yourself—thinking, “Why can’t I think of something to say?”—but this can be part of your body’s fight, flight, or freeze response to anxiety.
  • Over-apologizing and deferring to others instead of stating your own preferences: People with social anxiety often seek social approval.
  • Rumination: Replaying past conversations, focusing on something you think went wrong, or feeling that you were really embarrassing. Thinking about social interactions is normal, but if it causes distress and is hard to control, you may have social anxiety.
  • Perfectionism: Feeling that you have to know the perfect thing to say before you can speak.
  • Hiding behind your phone in public: Not for work or enjoyment, but to avoid engaging with others.

How can I become more confident in social situations?

Here are three tips you might find useful:

  • Remind yourself that everyone feels awkward sometimes. That normalizes the experience and helps you feel less alone.
  • Vocalize your feelings. For example, if you’re giving a speech, you might say, “I’m feeling nervous because I really want this to go well.” Naming it can disarm others and help you feel more confident.
  • Reframing your thoughts can build confidence. Instead of telling yourself, “I’m so awkward,” tell yourself, “A part of me feels anxious, and that’s okay. I’m going to do my best.” Coaching yourself with more balanced, supportive thoughts can make a difference.

How can a mental health professional help me with social anxiety?

Social anxiety is highly treatable, and cognitive behavioral therapy (CBT) is the gold standard. CBT helps you identify thoughts contributing to anxiety and use cognitive restructuring to examine them.

How does a therapist use cognitive behavioral therapy to treat social anxiety?

I would ask you to recall positive social experiences to challenge self-critical thoughts, like “I can never connect with people.” Cognitive behavioral therapists work on helping you create more balanced thoughts—for example, “Sometimes I feel awkward, but I’ve also connected with others before.”

Therapists also assign gradual behavioral exposures—small tasks like ordering coffee and making eye contact with the cashier, then building up to things like attending a party. The goal is to break the cycle of avoidance and create opportunities to approach social situations.

Are there medications that treat social anxiety?

CBT is often very effective, but if symptoms remain or access is limited, medication may be a helpful additional support. Depending on how severe your anxiety is—especially if generalized anxiety is also present—we may refer you to a psychiatrist to discuss medication options.

What happens if I continue to avoid social situations?

Avoidance makes anxiety stronger. When you avoid a social situation, anxiety goes down short-term, but you don’t get the chance to learn that you can manage it.

Treatment isn’t about getting rid of anxiety—it’s about learning you can feel anxious and still engage meaningfully. The more you approach instead of avoiding, the more confidence you build.

How Can I Create Healthier Phone Habits? Three Tips From a Mount Sinai Psychologist

Phones have become a necessary part of life, but if you find yourself mindlessly scrolling or constantly reaching for your phone out of boredom, you may have a phone addiction.

“Addiction isn’t just about substances—it can also be behavioral,” says Naomi Dambreville, PhD, a licensed clinical child and adult psychologist at The Mount Sinai Hospital. “Phone addiction is compulsive and excessive phone use, feeling out of control, or distressed when away from your phone. If you feel withdrawal when not online or fear missing content, you may have a problem.”

Naomi Dambreville, PhD

In this Q&A, Dr. Dambreville, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, explains how to know if you might have an unhealthy relationship with your phone, and tips for using it in healthier ways.

What are some signs that I spend too much time on my phone or social media?
We live in a digital society and rely on phones for many everyday activities. It can be hard to realize phone use is a problem because it’s so convenient, but signs include:

  • Everything revolves around your phone. You shop, socialize, get news, and do almost everything through your phone—and rarely engage in real-life alternatives.
  • You have an automatic relationship with your phone. Every notification prompts an instant reaction, you check every direct message, constantly scroll, or have FOMO (fear of missing out)—especially if being offline makes you feel sad or out of the loop.
  • Trouble focusing. If you’re multitasking—watching TV and scrolling, talking to someone but still on your phone—or always reaching for your phone at work or in class.
  • Low tolerance for boredom. Your instinct is to grab your phone the moment you have nothing to do. Scrolling becomes a default time filler with no real purpose.
  • Physical symptoms—headaches, fatigue, sleep disruption, eye strain, and “digital thumb” (thumb, hand, or wrist pain from holding your phone for long periods).
  • Phone-related conflicts. Your phone causes conflicts in your relationships because your loved ones feel ignored.

How can I use my phone in healthier ways?

Here are three ways to create healthier phone habits:

  • Train your social media algorithms: Block unwanted content, use filters, and control what you see. Choose not to view certain images or videos.
  • Create rules around phone use. No phones at dinner, during conversations, or bedtime. For families, agree on time limits, app access, and talk about uncomfortable content.
  • Use the phone for connection, but notice when it causes discomfort. Align phone use with your values and make space for real-world experiences.

How does phone addiction, including doom scrolling, affect mental health?
Doom scrolling refers to consuming large amounts of news, often bad—for example, catastrophic storms, conflicts, or negative political content. We grab our phones to search for updates and end up exposed to real-time traumatic or distressing information.

This behavior becomes mindless. You might scroll to stay informed but end up feeling worse. Bad moods lead to more scrolling, which worsens the mood further. It affects attention, mood, self-esteem, and can trigger irritability, anxiety, or anger.

Do “digital detoxes” reduce phone addiction? How?
A digital detox helps reduce or stop phone use. It’s about breaking the cycle of compulsive use. Detoxing gives your mind and body a break and allows space to build new habits. Here’s how:

  • Start by building awareness. Notice what you use your phone for—shopping, paying bills, etc. Try doing some of those activities in real life. Spend an hour off your phone, and see how it feels.
  • Notice withdrawal reactions—thinking about your phone, missing notifications, or feeling uncomfortable without it. Use app limits and be intentional: “I’m checking my bank app” vs. “I ended up scrolling Instagram.”
  • Replace phone time with real-life activities—reading a book, joining a club, socializing in person, or trying a new hobby.

How can a mental health professional help?
People often seek help for anxiety, low self-esteem, or conflict—and phone use may be a factor. Therapists can help with behavior changes, digital detox plans, and social skills. They can also address phone-related issues like gambling, shopping, and excessive social media use, helping reduce dependency and improve well-being.

Stories Behind the Science: Dennis S. Charney, MD, and Psychiatry

Stories Behind the Science: Dennis S. Charney, MD, and Psychiatry

Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, created a legacy by serving as Dean for 18 years—one of the longest tenures of any medical school dean in the United States. His research career has been just as illustrious over the decades.

Rooted in psychiatry, pharmacology, and neurobiology, Dr. Charney’s research has resulted in treatment breakthroughs for depression, enhanced medical and scientific understanding, and led to two U.S. Food and Drug Administration (FDA)-approved therapies. He has published more than 800 articles, which have been cited more than 198,000 times, according to Google Scholar, and was elected to the prestigious National Academy of Medicine in 2000.

One of his biggest research milestones was discovering that ketamine can be used as a fast-acting antidepressant, offering a useful alternative for patients who do not respond well to conventional therapies. However, pursuing that discovery was not easy amid societal stigma at the time.

“We were looked at like we were pursuing a PCP study or something,” said Dr. Charney, referring to the recreational street drug. “But we knew we had something big on our hands. We were on the verge of discovering something that could change the lives of patients, and we were very motivated. We weren’t scared, and we went about doing it the right way.”

In addition to discovering the antidepressive effects of ketamine, Dr. Charney is known for his work on the science of resilience, and for his role in the first FDA-approved digital therapeutic for depression.

Read more below about the decades of Dr. Charney’s research efforts, and what it was like being at the frontier.

The Beginnings:
A Focus on Bringing
Bench to Bedside

A young Dr. Charney (right) with mentor and collaborator George Heninger, MD (left), photo taken in 1996.

In the early 1980s, working at the Yale School of Medicine in conjunction with the Connecticut Mental Health Center, Dr. Charney was focused on understanding the pathophysiology of serious forms of depression, along with panic and anxiety disorders and obsessive-compulsive disorder.

“We wanted to develop better treatments for these conditions,” said Dr. Charney.

At the time, the neurotransmitters serotonin and norepinephrine were known to be involved in some psychiatric conditions, and Dr. Charney and his team members were developing methods of examining those relationships closely.

“It’s fair to say we developed, at that time, more sophisticated ways of studying those neurotransmitters,” he said, adding, “although they’re probably not considered sophisticated today.”

Those efforts led to the study of yohimbine, an alkaloid of the bark of the yohimbe tree, which revealed that excessive norepinephrine function was involved in panic disorder and PTSD (Arch Gen Psychiatry, 1984, now JAMA Psychiatry).

“That study was a great example of a combination of going from the lab to studying patients,” he said.

While a number of serotonin and norepinephrine reuptake inhibitors were emerging at the time, Dr. Charney’s findings were showing that targeting these neurotransmitters alone were insufficient to move the needle on treating depression.

“However, I felt that just looking at serotonin and norepinephrine couldn’t tell us the whole story about depression,” said Dr. Charney.

Finding Alternatives: Ketamine and the Glutamate System

Starting in the late 1980s, the treatment of major depression moved toward using selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). However, there was still a notable proportion of patients for whom these drugs were not effective enough.

“In patients who were not doing better, we tried to augment the serotonin system,” said Dr. Charney. “It didn’t work.”

“With all the studies we’ve been doing in depression, we thought monoamines told only part of the story in depression,” he noted, referring to the class of neurotransmitters that includes dopamine, serotonin, and norepinephrine. “So we thought maybe there is another system that was, in part, regulated by the monoamines, but would be more fundamentally involved in depression.”

In the early 1990s, Dr. Charney and his collaborator at Yale, John H. Krystal, MD, began looking for a pathway affected by monoamine neurotransmitters, and through a logical progression of studies, focused on the glutamate system and, soon, on ketamine—an anesthetic with known effects on the glutamate system. This work yielded some of Dr. Charney’s top-cited papers (Arch Gen Psych, 1994).

In the mid-1990s, Drs. Charney and Krystal did a series of studies on ketamine, first on healthy volunteers and then a small trial on seven patients with major depressive disorder (MDD). The results were shocking.

“The patients got better in a few hours,” recalled Dr. Charney. “I was like, ‘Are you kidding me?’ As an investigator watching it, it was like a miracle.”

Dennis S. Charney, MD (right) with John H. Krystal, MD (left), being awarded the Colvin Prize at the Brain and Behavior Research Foundation Gala, November 2019.

Drs. Charney and Krystal published their findings (Biological Psychiatry, 2000), but faced skepticism from both the scientific and general communities. The study was dismissed as not being replicable, and additionally for the fact that the researchers were working with a compound that was stigmatized for its recreational use.

When Dr. Charney went to the National Institute of Mental Health (NIMH) in 2000, he sought to repeat history. “Nobody believed it, nobody was trying to replicate it, so we’re going to have to do it ourselves at NIMH,” he said. “In the second study, we replicated it dead on.”

At the end of his stint at NIMH in 2004, Dr. Charney brought his findings with him to the Mount Sinai School of Medicine (now the Icahn School of Medicine), where he began his career as Dean of Research.

Dr. Charney is a named co-inventor on patents filed by Mount Sinai relating to the use of ketamine for the treatment of treatment-resistant depression and suicidal ideation. Mount Sinai licensed those patents to Janssen Pharmaceuticals, Inc. for the development of SPRAVATO (esketamine) by Janssen, which received FDA approval in 2019. Its approval makes it the first antidepressant of its kind to target N-methyl-D-aspartate (NMDA) receptors—introducing the first new class of antidepressant drugs since the 1950s.

A Prescription for Resilience

In the 1990s, Dr. Charney turned his focus to studying trauma and PTSD, in collaboration with Steven M. Southwick, MD. That journey led to some of Dr. Charney’s most impactful work on understanding resilience.

“My buddy, Steve Southwick, was really involved in that work,” said Dr. Charney of his colleague, who passed away in 2022. “He’s on a lot of my papers, and he became my closest friend.” The ties between the two researchers dated back to before the 1980s.

Drs. Charney and Southwick tackled understanding PTSD from all angles—psychological, biological, social, pharmacological. Then, they had an idea to take their findings a step further to help patients.

“Back then, we thought, ‘If we studied people who were resilient—people who had been traumatized but didn’t develop PTSD—perhaps we could learn something from it, and apply those lessons to help patients with PTSD,” said Dr. Charney. “That’s how I ended up studying resilience for over 30 years.”

Dr. Charney’s paper on resilience (Am. J. Psychiatry, 2004) became one of his most cited works after his publications on ketamine in depression. He and Dr. Southwick then published a book called “Resilience: The Science of Mastering Life’s Greatest Challenges” (Cambridge University Press, 2012).

The book, now in its third edition, is rooted in the hundreds of interviews Drs. Charney and Southwick did with people who faced challenges in their lives—including prisoners of war and survivors of sexual and physical abuse. It includes a “prescription” for being resilient—10 steps that people can take to overcome life challenges.

From left to right, Dennis S. Charney, MD; Steven M. Southwick, MD; and John H. Krystal, MD.

“Not just for others—our research on resilience was also a personal journey,” said Dr. Charney. In 2016, Dr. Charney survived being shot, and he credits the lessons on resilience for overcoming that ordeal.

Those resilient factors also helped Dr. Charney navigate the stresses of the COVID-19 pandemic, and he established the Center for Stress, Resilience and Personal Growth in 2020 to extend that support to Mount Sinai staff.

Through Boldness,
a New Therapy Emerges

 

In 2024, the FDA approved a new class of treatments: digital therapeutics. In that class was REJOYN, a prescription smartphone app by Click Therapeutics and Otsuka Precision Health for major depressive disorder. That novel treatment had its beginnings through Dr. Charney’s research.

“This goes back to when we were interviewing prisoners of war who were subject to solitary confinement in Vietnam,” said Dr. Charney. “Some of them said that when they were in solitary, all they could do was think.”

A Life Magazine cover from 1967, featuring a prisoner of war from the Vietnam War, whom Drs. Charney and Southwick had interviewed as part of their research on resilience. That body of work eventually led to the development of Rejoyn, a digital app for treating depression.

Over time, some of those individuals reported developing cognitive capacities they never had before, such as being able to do complex multiplication with just their mind. “To me, that suggested evidence of neuroplasticity, where you can change the chemistry and circuits in your brain through repeated tasks,” said Dr. Charney.

With that inspiration, Dr. Charney pondered whether neuroplasticity could be tapped to “correct” the brain circuitry of patients with depression and improve their symptoms.

“We knew something about the circuits of depression that involved the prefrontal cortex and subcortical regions, like the amygdala. What if we developed a task that involved both of those regions?” he said.

Brian Iacoviello, PhD, Assistant Professor of Psychiatry at the Icahn School of Medicine, and Dr. Charney developed the Emotional Faces Memory Task and ran two randomized controlled studies. The findings (npj Digital Medicine, 2018) showed that patients who did the task repeatedly had improvements in their depression symptoms.

Drs. Charney and Iacoviello are co-inventors of patents filed by Mount Sinai for the Emotional Faces Memory Task intervention for the treatment of depression and related psychiatric disorders. Mount Sinai licensed the patents to Click Therapeutics, Inc. and Otsuka Precision Health for the development of REJOYN, a digital treatment for depression. REJOYN received FDA clearance in 2024, as the first prescription adjunctive treatment for adults with MDD.

“Like with ketamine for depression, I see going for a digital approach for depression as a story about being bold,” said Dr. Charney. “Each time, it was a realization that our current understanding isn’t enough, and it’s worth it to take a different approach.”

With more than 50 patents, and a slew of scientific achievements, what’s next for Dr. Charney? “Resilience will continue to inspire me after I step down as Dean,” he said.

Dr. Charney steps down as Dean from the Icahn School of Medicine on Monday, June 30, and Eric J. Nestler, MD, PhD, has been appointed Interim Dean.

“I’m going to need to figure out how to be inspired next. I’m going to continue my research in depression and resilience,” said Dr. Charney. One option that’s underway is working on the fourth edition of his book on resilience. But there might be other bold options out there too.

“I have two therapies on the market,” said Dr. Charney. “My goal is to discover a third. I’m not sure if anyone in psychiatry has ever done that.”